Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
Authors:
Open Access
Abstract
In the UGDP study, published in the 1970s, a high incidence of cardiovascular mortality was found in patients treated with the sulfonylurea agent tolbutamide. Impaired ischaemic preconditioning is presumed to be the most important mechanism for the excess cardiovascular mortality observed. However, as tolbutamide has only a low affinity for cardiac sulfonylurea receptors, interference with ischaemic preconditioning seems unlikely to account for this excess mortality. Several smaller studies also failed to establish a definite link between sulfonylurea treatment before acute myocardial infarction and in-hospital mortality. However, when the myocardium becomes exposed to repeated or prolonged periods of ischaemia, ischaemic preconditioning may become clinically important. Myocardial ischaemia can also develop during emergency or elective angioplasty and during coronary bypass surgery. Therefore discontinuation of sulfonylurea treatment should be considered in these circumstances.Keywords
This publication has 46 references indexed in Scilit:
- Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitusBMJ, 1997
- Sulfonylurea KATPBlockade in Type II Diabetes and Preconditioning in Cardiovascular DiseaseCirculation, 1996
- Cloning, Tissue Expression, and Chromosomal Localization of SUR2, the Putative Drug-Binding Subunit of Cardiac, Skeletal Muscle, and Vascular KATP ChannelsDiabetes, 1996
- Cardiovascular Effects of Conventional Sulfonylureas and GlimepirideHormone and Metabolic Research, 1996
- Cardiovascular effects of sulphonylurea derivativesDiabetologia, 1995
- Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.Circulation, 1994
- Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamideCardiovascular Research, 1993
- Sulfonylureas in NIDDMDiabetes Care, 1992
- Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.Circulation Research, 1992
- Oral Hypoglycemic AgentsNew England Journal of Medicine, 1989